Intact Vascular is advancing clinical science to improve the treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI) following standard and drug-coated balloon angioplasty. Investigators are currently conducting these clinical trials to study the use of the Tack Endovascular System® in new applications.STATUS: In follow up, enrollment complete (N=201)

DESCRIPTION: This multi-center, single-arm European study is designed to investigate the safety and efficacy of the Tack Endovascular System® for the repair of dissection(s) type(s) A through F resulting from post percutaneous transluminal angioplasty (PTA) using the Medtronic IN.PACT™ Admiral™ drug-coated angioplasty balloon in the superficial femoral and proximal popliteal arteries. This study includes a subgroup of patients with long arterial lesions.

To learn more about this study, visit www.clinicaltrials.gov.STATUS: In follow up, enrollment complete (N=233)

DESCRIPTION: This multi-center, global study is the first IDE clinical trial approved in the United States to investigate the safety and effectiveness of a permanent vascular implant in arteries below the knee. TOBA II BTK will evaluate the Tack Endovascular System® in subjects with peripheral arterial disease (PAD) and dissections resulting from percutaneous transluminal angioplasty (PTA) using a standard balloon in the mid/distal popliteal, tibial and/peroneal arteries.

To learn more about this study, visit www.clinicaltrials.gov.

Lutonix® is a registered trademark of BD Interventional.

IN.PACT® and Admiral® are registered trademarks of Medtronic, Inc.

Scroll to Top
Intact Vascular uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this.